PetVivo Holdings, Inc. has announced a significant development in its financial strategy by entering into a Subscription Agreement to raise $1 million in equity financing. This agreement, finalized on March 13, 2026, involves the issuance of 1,250,000 units at a purchase price of $0.80 per unit. Each unit comprises one share of restricted common stock and one warrant to purchase an additional share at an exercise price of $1.10, valid for three years from the issuance date. The company has already received $400,000 of the total offering proceeds, with the remaining $600,000 expected by April 15, 2026. Furthermore, the investor has the option to invest an additional $1.5 million for 1,875,000 units under similar terms, anticipated to be completed by June 30, 2026. This financing is crucial for PetVivo as it aims to enhance its operational capabilities and fund the commercialization of its lead product, Spryng™ with OsteoCushion™ Technology. The company emphasizes that the offering was conducted under the exemption from registration provided by Section 4(a)(2) of the Securities Act, ensuring compliance with regulatory standards. This strategic move is expected to bolster PetVivo's liquidity and support its growth initiatives in the competitive market of animal health products.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.